In Korea, the Ministry of Food and Drug Safety (MFDS) is in charge of regulating pharmaceutical products and services.
Pharmaceutical companies submit a Carbonic acid, lanthanum(3+) salt (3:2) Drug Master File in Korea (Carbonic acid, lanthanum(3+) salt (3:2) KDMF) to the MFDS, which includes comprehensive information about the production, processing, facilities, materials, packaging, and testing of Carbonic acid, lanthanum(3+) salt (3:2). The MFDS reviews the Carbonic acid, lanthanum(3+) salt (3:2) KDMF as part of the drug registration process and uses the information provided in the Carbonic acid, lanthanum(3+) salt (3:2) KDMF to evaluate the safety and efficacy of the drug.
After submitting a Carbonic acid, lanthanum(3+) salt (3:2) KDMF to the MFDS, the registered manufacturer can provide importers or distributors with the registration number without revealing confidential information to Korean business partners. Applicants seeking to register their Carbonic acid, lanthanum(3+) salt (3:2) API can apply through the Korea Drug Master File (KDMF).
click here to find a list of Carbonic acid, lanthanum(3+) salt (3:2) suppliers with KDMF on PharmaCompass.